Your browser doesn't support javascript.
loading
Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience.
De Sousa, Paul A; Steeg, Rachel; Wachter, Elisabeth; Bruce, Kevin; King, Jason; Hoeve, Marieke; Khadun, Shalinee; McConnachie, George; Holder, Julie; Kurtz, Andreas; Seltmann, Stefanie; Dewender, Johannes; Reimann, Sascha; Stacey, Glyn; O'Shea, Orla; Chapman, Charlotte; Healy, Lyn; Zimmermann, Heiko; Bolton, Bryan; Rawat, Trisha; Atkin, Isobel; Veiga, Anna; Kuebler, Bernd; Serano, Blanca Miranda; Saric, Tomo; Hescheler, Jürgen; Brüstle, Oliver; Peitz, Michael; Thiele, Cornelia; Geijsen, Niels; Holst, Bjørn; Clausen, Christian; Lako, Majlinda; Armstrong, Lyle; Gupta, Shailesh K; Kvist, Alexander J; Hicks, Ryan; Jonebring, Anna; Brolén, Gabriella; Ebneth, Andreas; Cabrera-Socorro, Alfredo; Foerch, Patrik; Geraerts, Martine; Stummann, Tina C; Harmon, Shawn; George, Carol; Streeter, Ian; Clarke, Laura; Parkinson, Helen; Harrison, Peter W.
Afiliação
  • De Sousa PA; Centre for Clinical Brain Sciences, Chancellors Building, 49 Little France Crescent, University of Edinburgh, Edinburgh EH16 4SB, UK; Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditr
  • Steeg R; Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK.
  • Wachter E; Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK.
  • Bruce K; Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK.
  • King J; Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK.
  • Hoeve M; Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK.
  • Khadun S; Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK.
  • McConnachie G; Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK.
  • Holder J; Roslin Cells Ltd(1), Head office, Nine Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, UK; EBiSC banking facility, Babraham Research Campus, B260 Meditrina, Cambridge CB22 3AT, UK.
  • Kurtz A; Charité - Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Augustenburger Platz, Berlin 13353, Germany.
  • Seltmann S; Charité - Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Augustenburger Platz, Berlin 13353, Germany.
  • Dewender J; Charité - Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Augustenburger Platz, Berlin 13353, Germany.
  • Reimann S; Charité - Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Augustenburger Platz, Berlin 13353, Germany.
  • Stacey G; UK Stem Cell Bank, Division of Advanced Therapies, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Authority, Blanche Lane, South Mimms, Hertfordshire, ENG 3GQ, UK.
  • O'Shea O; UK Stem Cell Bank, Division of Advanced Therapies, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Authority, Blanche Lane, South Mimms, Hertfordshire, ENG 3GQ, UK.
  • Chapman C; UK Stem Cell Bank, Division of Advanced Therapies, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Authority, Blanche Lane, South Mimms, Hertfordshire, ENG 3GQ, UK.
  • Healy L; UK Stem Cell Bank, Division of Advanced Therapies, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Authority, Blanche Lane, South Mimms, Hertfordshire, ENG 3GQ, UK.
  • Zimmermann H; Fraunhofer Institute for Biomedical Engineering (IBMT), Josef-von-Fraunhofer-Weg 1, 66280 Sulzbach, Germany; Molecular & Cellular Biotechnology/Nanotechnology, Saarland University, Campus, 66123 Saarbrücken, Germany.
  • Bolton B; European Collection of Authenticated Cell Cultures, Public Health England, Porton Down, Salisbury SP4 0JG, UK.
  • Rawat T; European Collection of Authenticated Cell Cultures, Public Health England, Porton Down, Salisbury SP4 0JG, UK.
  • Atkin I; European Collection of Authenticated Cell Cultures, Public Health England, Porton Down, Salisbury SP4 0JG, UK.
  • Veiga A; Barcelona Stem Cell Bank, Centre for Regenerative Medicine in Barcelona, C/Dr. Aiguader 88, 08003 Barcelona, Spain.
  • Kuebler B; Barcelona Stem Cell Bank, Centre for Regenerative Medicine in Barcelona, C/Dr. Aiguader 88, 08003 Barcelona, Spain.
  • Serano BM; Andalusian Public Health Care System, Avda Conocimiento sn, 18100 Armilla, Granada, Spain.
  • Saric T; Centre for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
  • Hescheler J; Centre for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty, University of Cologne, 50931 Cologne, Germany.
  • Brüstle O; Institute of Reconstructive Neurobiology, LIFE & BRAIN Centre, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.
  • Peitz M; Institute of Reconstructive Neurobiology, LIFE & BRAIN Centre, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.
  • Thiele C; Institute of Reconstructive Neurobiology, LIFE & BRAIN Centre, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.
  • Geijsen N; Hubrecht Institute for developmental biology and stem cell research, Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht University, Department of Clinical Sciences of Companion Animals and UMC Utrecht, 3584CT Utrecht, The Netherlands.
  • Holst B; Bioneer A/S, Kogle Alle 2, DK-2970 Hørsholm, Denmark.
  • Clausen C; Bioneer A/S, Kogle Alle 2, DK-2970 Hørsholm, Denmark.
  • Lako M; Institute for Genetic Medicine, University of Newcastle, Newcastle NE1 3BZ, United Kingdom.
  • Armstrong L; Institute for Genetic Medicine, University of Newcastle, Newcastle NE1 3BZ, United Kingdom.
  • Gupta SK; AstraZeneca, R&D, Innovative Medicines, Discovery Sciences, Reagents and Assay Development, HC3006, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Kvist AJ; AstraZeneca, R&D, Innovative Medicines, Discovery Sciences, Reagents and Assay Development, HC3006, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Hicks R; AstraZeneca, R&D, Innovative Medicines, Discovery Sciences, Reagents and Assay Development, HC3006, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Jonebring A; AstraZeneca, R&D, Innovative Medicines, Discovery Sciences, Reagents and Assay Development, HC3006, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Brolén G; AstraZeneca, R&D, Innovative Medicines, Discovery Sciences, Reagents and Assay Development, HC3006, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
  • Ebneth A; Janssen Research & Development (A Division of Janssen Pharmaceutica N.V), Neuroscience Therapeutic Area, Turnhoutseweg 30, 2340 Beerse, Belgium.
  • Cabrera-Socorro A; Janssen Research & Development (A Division of Janssen Pharmaceutica N.V), Neuroscience Therapeutic Area, Turnhoutseweg 30, 2340 Beerse, Belgium.
  • Foerch P; UCB Biopharma (since May 2014), Discovery Research, Chemin du Foriest, Braine l'Alleud B-1420, Belgium.
  • Geraerts M; UCB Biopharma (since May 2014), Discovery Research, Chemin du Foriest, Braine l'Alleud B-1420, Belgium.
  • Stummann TC; H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark.
  • Harmon S; University of Edinburgh School of Law, Old College, South Bridge, Edinburgh EH8 9YL, UK.
  • George C; University of Edinburgh School of Law, Old College, South Bridge, Edinburgh EH8 9YL, UK.
  • Streeter I; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK.
  • Clarke L; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK.
  • Parkinson H; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK.
  • Harrison PW; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK.
Stem Cell Res ; 20: 105-114, 2017 04.
Article em En | MEDLINE | ID: mdl-28334554
ABSTRACT
A fast track "Hot Start" process was implemented to launch the European Bank for Induced Pluripotent Stem Cells (EBiSC) to provide early release of a range of established control and disease linked human induced pluripotent stem cell (hiPSC) lines. Established practice amongst consortium members was surveyed to arrive at harmonised and publically accessible Standard Operations Procedures (SOPs) for tissue procurement, bio-sample tracking, iPSC expansion, cryopreservation, qualification and distribution to the research community. These were implemented to create a quality managed foundational collection of lines and associated data made available for distribution. Here we report on the successful outcome of this experience and work flow for banking and facilitating access to an otherwise disparate European resource, with lessons to benefit the international research community. ETOC The report focuses on the EBiSC experience of rapidly establishing an operational capacity to procure, bank and distribute a foundational collection of established hiPSC lines. It validates the feasibility and defines the challenges of harnessing and integrating the capability and productivity of centres across Europe using commonly available resources currently in the field.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bancos de Espécimes Biológicos / Células-Tronco Pluripotentes Induzidas Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Stem Cell Res Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bancos de Espécimes Biológicos / Células-Tronco Pluripotentes Induzidas Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Stem Cell Res Ano de publicação: 2017 Tipo de documento: Article